GlassScriptPhysician profile
Jeffrey Slaney Williams
NPI 1225024490
$6,832.72
in general payments reported to CMS, 2019-2025
25 companies · $1,479 in 2025
The $1,479 reported for 2025 was more than what 95% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $914 · 2020: $541 · 2021: $1,064 · 2022: $1,237 · 2023: $496 · 2024: $1,101 · 2025: $1,479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,076.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,076.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $662.00 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Dompe US, INC. | $638.68 | 2022-2025 | Oxervate |
| Novartis Pharmaceuticals Corporation | $631.97 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $617.74 | 2020-2025 | Cequa |
| Allergan, INC. | $605.54 | 2019-2022 | |
| Alcon Vision LLC | $518.47 | 2020-2025 | Tryptyr, Eysuvis, Precision 1 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $422.32 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $409.28 | 2021-2022 | |
| Oyster Point Pharma, INC. | $336.97 | 2022-2025 | Tyrvaya, Ryzumvi |
| Harrow Eye, LLC | $277.80 | 2024-2025 | Vevye |
| Ocular Therapeutix, INC. | $274.58 | 2022-2025 | Dextenza |
| Maculogix, INC. | $233.74 | 2019-2021 | |
| Shire North American Group INC | $206.85 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $189.36 | 2024-2025 | Xdemvy |
| Biohaven Pharmaceutical Holding Company LTD. | $182.49 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $124.59 | 2022 | |
| Glaukos Corporation | $124.49 | 2021 | |
| Rxsight INC | $124.43 | 2023 | Rxsight Contact Lens, Rxsight Light Adjustable Lens (Rxlal), Rxsight Injector Cartridge |
| Coopervision INC. | $94.49 | 2019-2022 | |
| Heru, INC. | $54.79 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $26.54 | 2021 | |
| Visioneering Technologies, INC. | $23.94 | 2022 | |
| Aerie Pharmaceuticals, INC. | $19.80 | 2019 | |
| Sight Sciences, INC. | $16.36 | 2022 | |
| Eyevance Pharmaceuticals LLC | $15.50 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.